MAYNE PHARMA GROUP LIMITED — Capital/Financing Update 2015

Feb 23, 2015

==> picture [116 x 45] intentionally omitted <==

ASX Announcement

MAYNE PHARMA COMPLETES ACQUISITION OF DORYX ® ASSETS

24 February 2015, Melbourne Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the completion of the acquisition of the Doryx ® brand and related assets for US$50m. The acquisition, announced on 10 February 2015, was funded by the proceeds of the institutional entitlement offer and institutional placement.

Mayne Pharma CEO Mr Scott Richards said, “We are pleased to have completed the acquisition of the Doryx ® assets slightly ahead of schedule. The acquisition is extremely exciting for Mayne Pharma and will transform the business in terms of earnings and cashflow.”

For further information contact:

Scott Richards +61 8 8209 2410 Lisa Pendlebury +61 419 548 434, lisa.pendlebury@maynepharma.com

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company that develops and manufactures branded and generic products, which it distributes globally; either directly or through distribution partners and also provides contract development and manufacturing services.

Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that have been marketed around the world.

Mayne Pharma has two drug development and manufacturing facilities based in Salisbury, Australia and Greenville, USA with expertise in formulation complex oral dose forms including highly potent compounds, controlled substances, modified release products and inherently unstable compounds.

==> picture [125 x 126] intentionally omitted <==

Page 1